Cargando…

Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy

The immune response against cancer is orchestrated by various parameters and site-dependent specificities have been poorly investigated. In our analyses of ten different cancer types, we describe elevated infiltration by regulatory T cells as the most common feature, while other lymphocyte subsets a...

Descripción completa

Detalles Bibliográficos
Autores principales: Thelen, Martin, Wennhold, Kerstin, Lehmann, Jonas, Garcia-Marquez, Maria, Klein, Sebastian, Kochen, Elena, Lohneis, Philipp, Lechner, Axel, Wagener-Ryczek, Svenja, Plum, Patrick Sven, Velazquez Camacho, Oscar, Pfister, David, Dörr, Fabian, Heldwein, Matthias, Hekmat, Khosro, Beutner, Dirk, Klussmann, Jens Peter, Thangarajah, Fabinshy, Ratiu, Dominik, Malter, Wolfram, Merkelbach-Bruse, Sabine, Bruns, Christiane Josephine, Quaas, Alexander, von Bergwelt-Baildon, Michael, Schlößer, Hans A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208982/
https://www.ncbi.nlm.nih.gov/pubmed/34135436
http://dx.doi.org/10.1038/s41698-021-00196-x
_version_ 1783709033882976256
author Thelen, Martin
Wennhold, Kerstin
Lehmann, Jonas
Garcia-Marquez, Maria
Klein, Sebastian
Kochen, Elena
Lohneis, Philipp
Lechner, Axel
Wagener-Ryczek, Svenja
Plum, Patrick Sven
Velazquez Camacho, Oscar
Pfister, David
Dörr, Fabian
Heldwein, Matthias
Hekmat, Khosro
Beutner, Dirk
Klussmann, Jens Peter
Thangarajah, Fabinshy
Ratiu, Dominik
Malter, Wolfram
Merkelbach-Bruse, Sabine
Bruns, Christiane Josephine
Quaas, Alexander
von Bergwelt-Baildon, Michael
Schlößer, Hans A.
author_facet Thelen, Martin
Wennhold, Kerstin
Lehmann, Jonas
Garcia-Marquez, Maria
Klein, Sebastian
Kochen, Elena
Lohneis, Philipp
Lechner, Axel
Wagener-Ryczek, Svenja
Plum, Patrick Sven
Velazquez Camacho, Oscar
Pfister, David
Dörr, Fabian
Heldwein, Matthias
Hekmat, Khosro
Beutner, Dirk
Klussmann, Jens Peter
Thangarajah, Fabinshy
Ratiu, Dominik
Malter, Wolfram
Merkelbach-Bruse, Sabine
Bruns, Christiane Josephine
Quaas, Alexander
von Bergwelt-Baildon, Michael
Schlößer, Hans A.
author_sort Thelen, Martin
collection PubMed
description The immune response against cancer is orchestrated by various parameters and site-dependent specificities have been poorly investigated. In our analyses of ten different cancer types, we describe elevated infiltration by regulatory T cells as the most common feature, while other lymphocyte subsets and also expression of immune-regulatory molecules on tumor-infiltrating lymphocytes showed site-specific variation. Multiparametric analyses of these data identified similarities of renal and liver or lung with head and neck cancer. Co-expression of immune-inhibitory ligands on tumor cells was most frequent in colorectal, lung and ovarian cancer. Genes related to antigen presentation were frequently dysregulated in liver and lung cancer. Expression of co-inhibitory molecules on tumor-infiltrating T cells accumulated in advanced stages while T-cell abundance was related to enhanced expression of genes related to antigen presentation. Our results promote evaluation of cancer-specific or even personalized immunotherapeutic combinations to overcome primary or secondary resistance as major limitation of immune-checkpoint inhibition.
format Online
Article
Text
id pubmed-8208982
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82089822021-07-01 Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy Thelen, Martin Wennhold, Kerstin Lehmann, Jonas Garcia-Marquez, Maria Klein, Sebastian Kochen, Elena Lohneis, Philipp Lechner, Axel Wagener-Ryczek, Svenja Plum, Patrick Sven Velazquez Camacho, Oscar Pfister, David Dörr, Fabian Heldwein, Matthias Hekmat, Khosro Beutner, Dirk Klussmann, Jens Peter Thangarajah, Fabinshy Ratiu, Dominik Malter, Wolfram Merkelbach-Bruse, Sabine Bruns, Christiane Josephine Quaas, Alexander von Bergwelt-Baildon, Michael Schlößer, Hans A. NPJ Precis Oncol Article The immune response against cancer is orchestrated by various parameters and site-dependent specificities have been poorly investigated. In our analyses of ten different cancer types, we describe elevated infiltration by regulatory T cells as the most common feature, while other lymphocyte subsets and also expression of immune-regulatory molecules on tumor-infiltrating lymphocytes showed site-specific variation. Multiparametric analyses of these data identified similarities of renal and liver or lung with head and neck cancer. Co-expression of immune-inhibitory ligands on tumor cells was most frequent in colorectal, lung and ovarian cancer. Genes related to antigen presentation were frequently dysregulated in liver and lung cancer. Expression of co-inhibitory molecules on tumor-infiltrating T cells accumulated in advanced stages while T-cell abundance was related to enhanced expression of genes related to antigen presentation. Our results promote evaluation of cancer-specific or even personalized immunotherapeutic combinations to overcome primary or secondary resistance as major limitation of immune-checkpoint inhibition. Nature Publishing Group UK 2021-06-16 /pmc/articles/PMC8208982/ /pubmed/34135436 http://dx.doi.org/10.1038/s41698-021-00196-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Thelen, Martin
Wennhold, Kerstin
Lehmann, Jonas
Garcia-Marquez, Maria
Klein, Sebastian
Kochen, Elena
Lohneis, Philipp
Lechner, Axel
Wagener-Ryczek, Svenja
Plum, Patrick Sven
Velazquez Camacho, Oscar
Pfister, David
Dörr, Fabian
Heldwein, Matthias
Hekmat, Khosro
Beutner, Dirk
Klussmann, Jens Peter
Thangarajah, Fabinshy
Ratiu, Dominik
Malter, Wolfram
Merkelbach-Bruse, Sabine
Bruns, Christiane Josephine
Quaas, Alexander
von Bergwelt-Baildon, Michael
Schlößer, Hans A.
Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
title Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
title_full Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
title_fullStr Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
title_full_unstemmed Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
title_short Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
title_sort cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208982/
https://www.ncbi.nlm.nih.gov/pubmed/34135436
http://dx.doi.org/10.1038/s41698-021-00196-x
work_keys_str_mv AT thelenmartin cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT wennholdkerstin cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT lehmannjonas cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT garciamarquezmaria cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT kleinsebastian cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT kochenelena cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT lohneisphilipp cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT lechneraxel cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT wagenerryczeksvenja cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT plumpatricksven cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT velazquezcamachooscar cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT pfisterdavid cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT dorrfabian cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT heldweinmatthias cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT hekmatkhosro cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT beutnerdirk cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT klussmannjenspeter cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT thangarajahfabinshy cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT ratiudominik cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT malterwolfram cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT merkelbachbrusesabine cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT brunschristianejosephine cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT quaasalexander cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT vonbergweltbaildonmichael cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy
AT schloßerhansa cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy